

YU et al.

Examiner:

Unknown

Serial No.:

09/787328

Group Art Unit:

Unknown

16 March 2001

Docket:

9548.50USWO

Date:

16 June 2001

NEW HUMAN HEPATOMA-DERIVED GROWTH FACTOR ENCODING SEQUENCE AND POLYPEPTIDE ENCODED BY SUCH DNA SEQUENCE AND PRODUCING METHOD

THEREOF

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: , Commissioner for Patents, Washington, D.C. 20231, on 15 June 2001/

Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

☐ Transmittal Sheet in duplicate containing Certificate of Mailing

Information Disclosure Statement, Form 1449, 10 Reference(s)

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C. P.O. Box 2903, Minneapolis, MN 55402-0903 612.332.5300

PATENT TRADEMARK OFFICE


Name: Michael D. Schumann

Reg. No.: 30,422

MDS/klj







PATENT

ES/DL09/787328

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

YU et al.

Examiner:

Unknown

al No.

09/787328

Group Art Unit:

Unknown

Filed:

16 March 2001

Docket No.:

9548.50USWO

Title:

NEW HUMAN HEPATOMA-DERIVED GROWTH FACTOR

ENCODING SEQUENCE AND POLYPEPTIDE ENCODED BY SUCH

DNA SEQUENCE AND PRODUCING METHOD THEREOF

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on 15 Juny 2001

By:

Kate Jochman

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):

An English abstract only is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or



not "prior art." Moreover, Applicants do not

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.

P.O. Box 2903

Minneapolis, MN 55402-0903

(612)332.5300

D.

Michael D. Schumann

Reg. No. 30,422

MDS/klj

Dated: 15 June 2001

2





PE	DEFORMATION DISCLOSURE STATEMENT
/ 0	[a]

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	Application Number:
9548.50USWO	09/787328

Applicant: YU et al.

Filing Date: 16 March 2001 Group Art Unit: Unknown

				U.S. PATENT DOCUMEN	TS				
EXAMINER INITIAL			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		 							
	J.,		FC	DREIGN PATENT DOCUM	ENTS	<u> </u>			
	DOCUMENT NO.		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
				YES			NO		
	9252777		30.09.1997	Japan			Abstract Only		
	6343470		20.12.1994	Japan			Abstract Only		
	05134258		20.12.1994	Japan			Abstract Only		
	08064001		30.09.1997	Japan			Abstract Only		
4									
	1								
		.							
	···	ОТН	ER DOCUMEN	TS (Including Author, Title, I	Date, Pertinent Pag	es, Etc.)			
		Izumoto et al., "Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus," <i>Biochem. Biophys. Res. Commun.</i> 238 (1), 26-32 (1997).							
		Nakamura et al., "Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homolog with high mobility group-1 protein," <i>J. Biol. Chem.</i> 269 (40), 2514325149 (1994).							
		Nakamura et al., "Partial purification and characterization of human hepatoma-derived growth factor," Clin. Chim. Acta. 183 (2 273-284 (1989).							
		Jhappan et al., "TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas," <i>Cell</i> Vol. 61, 1137-1146 (1990).							
		Kan et al., "Heparin-binding growth factor type 1 (acidic fibroblast growth factor): A potential biphasic autocrine and paracrine regulator of hepatocyte regeneration," <i>Proc. Natl. Acad. Sci.</i> Vol. 86, 7432-7436 (1989).							
				nor cells synthesize an endoth cad. Sci. Vol. 83, 2448-2452 (ctor that is structura	ally related to bas	ic fibroblas	

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.